Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial.
Clicks: 466
ID: 48923
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
83.7
/100
445 views
317 readers
Trending
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Saffron (.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. 60 participants finished the study. Patients who received either saffron or citalopram showed significant improvement in scores of the Hamilton Rating Scale for Depression (P-value<0.001 in both groups) and Hamilton Rating Scale for Anxiety (P-value<0.001 in both groups). Comparison of score changes between the 2 trial arms showed no significant difference (P-value=0.984). Frequency of side effects was not significantly different between the 2 groups. The present study indicates saffron as a potential efficacious and tolerable treatment for major depressive disorder with anxious distress.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (86 words).
Try re-searching for a better abstract.
| Reference Key |
ghajar2017crocuspharmacopsychiatry
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ghajar, A;Neishabouri, S M;Velayati, N;Jahangard, L;Matinnia, N;Haghighi, M;Ghaleiha, A;Afarideh, M;Salimi, S;Meysamie, A;Akhondzadeh, S; |
| Journal | pharmacopsychiatry |
| Year | 2017 |
| DOI |
10.1055/s-0042-116159
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.